MoonLake Immunotherapeutics Prices Public Offering at $20 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: Newsfilter
- Offering Size: MoonLake Immunotherapeutics has priced its public offering at $20.00 per share for 9 million Class A ordinary shares, expecting to raise approximately $200 million, indicating strong market interest in its innovative therapies.
- Pre-Funded Warrant Option: The company is also offering pre-funded warrants for 1 million Class A ordinary shares at $19.9999, allowing investors to exercise immediately, which enhances the flexibility of capital raising.
- Clear Use of Proceeds: MoonLake intends to utilize the proceeds for the research and commercialization activities of sonelokimab, reflecting the company's confidence in this new therapy and aiming to address the urgent market need for treatments of inflammatory diseases.
- Strong Underwriter Lineup: The offering is being underwritten by prominent investment banks including Leerink Partners and Guggenheim Securities, which bolsters market confidence and attractiveness of the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 22.160
Low
5.00
Averages
24.10
High
45.00
Current: 22.160
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MoonLake Immunotherapeutics Prices Public Offering at $20 per Share
- Offering Size: MoonLake Immunotherapeutics has priced its public offering at $20.00 per share for 9 million Class A ordinary shares, expecting to raise approximately $200 million, indicating strong market interest in its innovative therapies.
- Pre-Funded Warrant Option: The company is also offering pre-funded warrants for 1 million Class A ordinary shares at $19.9999, allowing investors to exercise immediately, which enhances the flexibility of capital raising.
- Clear Use of Proceeds: MoonLake intends to utilize the proceeds for the research and commercialization activities of sonelokimab, reflecting the company's confidence in this new therapy and aiming to address the urgent market need for treatments of inflammatory diseases.
- Strong Underwriter Lineup: The offering is being underwritten by prominent investment banks including Leerink Partners and Guggenheim Securities, which bolsters market confidence and attractiveness of the offering.
See More
MoonLake Immunotherapeutics Raises $150 Million in Public Offering
- Funding Size: MoonLake Immunotherapeutics announced a $150 million public offering, intending to raise funds through the issuance of Class A ordinary shares and pre-funded warrants, aimed at supporting its key R&D projects.
- Use of Proceeds: The net proceeds from this offering will be allocated to the research, development, and pre-commercialization of its lead investigational 40-kDa humanized nanobody, Sonelokimab, as well as for general corporate purposes, indicating the company's commitment to future product launches.
- Clinical Progress: The company has made significant strides in clinical trials for Sonelokimab targeting Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA), particularly with positive 52-week results from the VELA-1 and VELA-2 trials demonstrating promising efficacy.
- Market Performance: MLTX stock has traded between $5.95 and $62.75 over the past year, closing at $22.16 on Monday with a 15.36% increase, although it dipped 2.53% in after-hours trading, reflecting overall market recognition of its future potential.
See More
MoonLake Immunotherapeutics Proposes $150M Public Offering
- Public Offering Plan: MoonLake Immunotherapeutics has proposed a public offering of $150 million in Class A ordinary shares, along with pre-funded warrants for certain investors, which is expected to provide substantial funding to support research and commercialization activities.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in Class A ordinary shares, allowing flexibility to adjust the financing scale based on market demand.
- Clear Use of Proceeds: The net proceeds will primarily support the development of Sonelokimab, MoonLake's lead drug candidate, which could present significant market opportunities if regulatory approval is obtained, while remaining funds will be allocated to general corporate purposes to ensure operational stability.
- Market Reaction: Following the announcement of the public offering, MLTX shares fell 3.4% in after-hours trading, reflecting a cautious market sentiment regarding the financing plan, which may impact investor confidence in the company's future growth.
See More
MoonLake Immunotherapeutics Shares Surge 15% on Positive Trial Results
- Clinical Trial Results: MoonLake's final Week 52 results indicate that approximately two-thirds of patients achieved at least a 75% reduction in painful abscesses and nodules, with one-third achieving complete clearance, suggesting significant efficacy that could reshape market dynamics.
- FDA Application Plans: The company plans to submit its biologics license application to the FDA by the end of September, expected to include data from both adults and adolescents, which could expedite the drug's market entry and enhance the company's competitive edge.
- Surge in Investor Sentiment: Retail investor sentiment around MLTX surged from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume significantly increasing, reflecting strong market confidence in the company's growth potential, with expectations of a $5 billion market cap increase by year-end.
- Optimistic Analyst Ratings: According to Koyfin, 11 out of 15 analysts covering MLTX rate it 'Buy' or higher, with a 12-month average price target of $27.62, representing about a 25% upside from the current stock price, indicating a positive outlook for its future performance.
See More
Middle East Tensions Ease Amid New China Trade Restrictions
- Middle East Peace Progress: A joint statement from Qatar and Pakistan indicates that the U.S. and Iran have agreed to a 60-day roadmap for peace, which, while easing tensions, leaves investors cautious about the potential impacts on market stability.
- Escalating Trade Restrictions: China has implemented strict dual-use export controls targeting specific U.S. defense, technology, and rare earth companies, which could pose significant operational challenges for these firms and affect overall market sentiment.
- Mixed U.S. Stock Futures: Following the Juneteenth holiday, U.S. stock futures showed mixed results, with Nasdaq futures flat while S&P 500 and Dow futures fell by 0.1% and 0.3% respectively, reflecting market caution ahead of key economic data releases.
- Earnings Reports in Focus: Investors are closely watching for upcoming earnings reports from Micron Technology and the core Personal Consumption Expenditures data, which are expected to provide critical insights into the Federal Reserve's rate direction and influence market trends.
See More
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results for Sonelokimab
- Clinical Trial Results: MoonLake Immunotherapeutics announced that in its Phase 3 VELA-1 and VELA-2 trials, 67.2% of patients treated with Sonelokimab achieved HiSCR75 at Week 52, indicating significant efficacy in treating moderate-to-severe hidradenitis suppurativa, which could enhance the company's market share in this area.
- Consistent Safety Profile: The safety profile of Sonelokimab in the VELA clinical programs remained stable over time with no new safety signals detected, providing confidence for future regulatory approvals and potentially accelerating the FDA review process.
- Upcoming Milestones: The company expects to submit a Biologics License Application (BLA) for Sonelokimab by the end of September 2026, and plans to release primary endpoint data from the Phase 3 IZAR-2 trial in PsA in the second half of 2026, laying the groundwork for future product line expansion.
- Investor Day Event: MoonLake is hosting an investor day webcast today to discuss clinical data and guidance on upcoming events, which is expected to attract investor interest and further enhance the company's image in the capital markets.
See More
MoonLake Immunotherapeutics Prices Public Offering at $20 per Share
- Offering Size: MoonLake Immunotherapeutics has priced its public offering at $20.00 per share for 9 million Class A ordinary shares, expecting to raise approximately $200 million, indicating strong market interest in its innovative therapies.
- Pre-Funded Warrant Option: The company is also offering pre-funded warrants for 1 million Class A ordinary shares at $19.9999, allowing investors to exercise immediately, which enhances the flexibility of capital raising.
- Clear Use of Proceeds: MoonLake intends to utilize the proceeds for the research and commercialization activities of sonelokimab, reflecting the company's confidence in this new therapy and aiming to address the urgent market need for treatments of inflammatory diseases.
- Strong Underwriter Lineup: The offering is being underwritten by prominent investment banks including Leerink Partners and Guggenheim Securities, which bolsters market confidence and attractiveness of the offering.
See More
MoonLake Immunotherapeutics Raises $150 Million in Public Offering
- Funding Size: MoonLake Immunotherapeutics announced a $150 million public offering, intending to raise funds through the issuance of Class A ordinary shares and pre-funded warrants, aimed at supporting its key R&D projects.
- Use of Proceeds: The net proceeds from this offering will be allocated to the research, development, and pre-commercialization of its lead investigational 40-kDa humanized nanobody, Sonelokimab, as well as for general corporate purposes, indicating the company's commitment to future product launches.
- Clinical Progress: The company has made significant strides in clinical trials for Sonelokimab targeting Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA), particularly with positive 52-week results from the VELA-1 and VELA-2 trials demonstrating promising efficacy.
- Market Performance: MLTX stock has traded between $5.95 and $62.75 over the past year, closing at $22.16 on Monday with a 15.36% increase, although it dipped 2.53% in after-hours trading, reflecting overall market recognition of its future potential.
See More
MoonLake Immunotherapeutics Proposes $150M Public Offering
- Public Offering Plan: MoonLake Immunotherapeutics has proposed a public offering of $150 million in Class A ordinary shares, along with pre-funded warrants for certain investors, which is expected to provide substantial funding to support research and commercialization activities.
- Underwriter Option: The company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in Class A ordinary shares, allowing flexibility to adjust the financing scale based on market demand.
- Clear Use of Proceeds: The net proceeds will primarily support the development of Sonelokimab, MoonLake's lead drug candidate, which could present significant market opportunities if regulatory approval is obtained, while remaining funds will be allocated to general corporate purposes to ensure operational stability.
- Market Reaction: Following the announcement of the public offering, MLTX shares fell 3.4% in after-hours trading, reflecting a cautious market sentiment regarding the financing plan, which may impact investor confidence in the company's future growth.
See More
MoonLake Immunotherapeutics Shares Surge 15% on Positive Trial Results
- Clinical Trial Results: MoonLake's final Week 52 results indicate that approximately two-thirds of patients achieved at least a 75% reduction in painful abscesses and nodules, with one-third achieving complete clearance, suggesting significant efficacy that could reshape market dynamics.
- FDA Application Plans: The company plans to submit its biologics license application to the FDA by the end of September, expected to include data from both adults and adolescents, which could expedite the drug's market entry and enhance the company's competitive edge.
- Surge in Investor Sentiment: Retail investor sentiment around MLTX surged from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume significantly increasing, reflecting strong market confidence in the company's growth potential, with expectations of a $5 billion market cap increase by year-end.
- Optimistic Analyst Ratings: According to Koyfin, 11 out of 15 analysts covering MLTX rate it 'Buy' or higher, with a 12-month average price target of $27.62, representing about a 25% upside from the current stock price, indicating a positive outlook for its future performance.
See More
Middle East Tensions Ease Amid New China Trade Restrictions
- Middle East Peace Progress: A joint statement from Qatar and Pakistan indicates that the U.S. and Iran have agreed to a 60-day roadmap for peace, which, while easing tensions, leaves investors cautious about the potential impacts on market stability.
- Escalating Trade Restrictions: China has implemented strict dual-use export controls targeting specific U.S. defense, technology, and rare earth companies, which could pose significant operational challenges for these firms and affect overall market sentiment.
- Mixed U.S. Stock Futures: Following the Juneteenth holiday, U.S. stock futures showed mixed results, with Nasdaq futures flat while S&P 500 and Dow futures fell by 0.1% and 0.3% respectively, reflecting market caution ahead of key economic data releases.
- Earnings Reports in Focus: Investors are closely watching for upcoming earnings reports from Micron Technology and the core Personal Consumption Expenditures data, which are expected to provide critical insights into the Federal Reserve's rate direction and influence market trends.
See More
MoonLake Immunotherapeutics Reports Positive Phase 3 Trial Results for Sonelokimab
- Clinical Trial Results: MoonLake Immunotherapeutics announced that in its Phase 3 VELA-1 and VELA-2 trials, 67.2% of patients treated with Sonelokimab achieved HiSCR75 at Week 52, indicating significant efficacy in treating moderate-to-severe hidradenitis suppurativa, which could enhance the company's market share in this area.
- Consistent Safety Profile: The safety profile of Sonelokimab in the VELA clinical programs remained stable over time with no new safety signals detected, providing confidence for future regulatory approvals and potentially accelerating the FDA review process.
- Upcoming Milestones: The company expects to submit a Biologics License Application (BLA) for Sonelokimab by the end of September 2026, and plans to release primary endpoint data from the Phase 3 IZAR-2 trial in PsA in the second half of 2026, laying the groundwork for future product line expansion.
- Investor Day Event: MoonLake is hosting an investor day webcast today to discuss clinical data and guidance on upcoming events, which is expected to attract investor interest and further enhance the company's image in the capital markets.
See More
